medigraphic.com
ISSN 1560-4381 (Print)

2020, Number 2

<< Back Next >>

Correo Científico Médico 2020; 24 (2)

Hypertriglyceridemia: classification, cardiovascular risk and therapeutic behavior

González BSN, Feria DGE, Valdés CRC, Panchana YSF, Jara RIG

Language: Spanish
References: 32
Page: 701-719
PDF size: 281.20 Kb.


ABSTRACT

Hypertriglyceridemia is a common condition due to genetic alterations or primary and secondary to disease or medication. Its main cause is an unhealthy lifestyle that includes excessive consumption of food rich in carbohydrates and fats, lack of physical activity and heavy intake of alcoholic beverages, which is often accompanied by overweight and obesity. This literature review details the classification of hypertriglyceridemia, associated cardiovascular risk and therapeutic behavior with lifestyle modifications and lipid-lowering drugs such as statins, ezetimibe, PCSK9 inhibitors, fibrates, omega-3 fatty acids and niacin; for this purpose, a critical review of the literature was conducted in PubMed, Scopus, MedicalKey and SciELO.


REFERENCES

  1. Gambetta JC, Araujo MB, Chiesa P. Dislipemias en la edad pediátrica. Importancia del diagnóstico y tratamiento precoces. Rev Urug Cardiol. 2019 [citado 01/02/ 2020]; 34(3): 208-238. Disponible en: http://www.scielo.edu.uy/scielo.php?script=sci_arttext&pid=S168804202019000300208&lng=es

  2. Laufs U, Parhofer KG, Ginsberg HN, Hegele RA. Clinical review on triglycerides. Eur Heart J. 2020[citado 01/02/2020]; 41: 99–109c. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938588/pdf/ehz785.pdf

  3. Shemesh E, Zafrir B. Hypertriglyceridemia-Related Pancreatitis In Patients With Type 2 Diabetes: Links And Risks. Diabetes Metab Syndr Obes. 2019[citado 01/02/2020];12: 2041–2052. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6789969/pdf/dmso-12-2041.pdf

  4. Diéguez Martínez M, Miguel Soca PE, Rodríguez Hernández R, López Báster J, Ponce de León D, Reyna Carralero JL. Prevalencia de hipertrigliceridemia y factores de riesgo cardiovascular en estudiantes de la Universidad de Ciencias Médicas. Holguín, 2014-2015. Medisur. 2018[citado 01 /02/ 2020]; 16 (1): 35-46. http://scielo.sld.cu/pdf/ms/v16n1/ms07116.pdf

  5. Miguel Soca P, Sarmiento Teruel Y, Mariño Soler A, Llorente Columbié Y, Rodríguez Graña T, Peña González M. Prevalencia de enfermedades crónicas no transmisibles y factores de riesgo en adultos mayores de Holguín. Rev Finlay. 2017 [citado 01/02/2020];7(3): 155-167. Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S222124342017000300002&lng=es

  6. Miguel Soca PE, Rivas Estévez M, Sarmiento Teruel Y, Mariño Soler AL, Marrero Hidalgo M, Mosqueda Batista L, et al. Prevalence of metabolic syndrome risk factors in adults in Holguin, Cuba (2004-2013). MEDICC Review. 2016[citado 01/02/2020];18(1–2):28–33. Disponible en: https://www.medigraphic.com/pdfs/medicreview/mrw-2016/mrw161_2g.pdf

  7. Esparza MI, Li X, Adams-Huet B, Vasandani C, Vora A, Das SR, et al. Very Severe Hypertriglyceridemia in a Large US County Health Care System: Associated Conditions and Management. J Endocr Soc. 2019[citado 01/02/2020]; 3(8): 1595–1607. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6676078/pdf/js.2019-00129.pdf

  8. Parhofer KG, Laufs U. The Diagnosis and Treatment of Hypertriglyceridemia. Dtsch Arztebl Int. 2019[citado 01/02/2020];116(49):825-832.Disponible en: https://www.aerzteblatt.de/pdf.asp?id=211103

  9. Elkins C, Friedrich D. Hypertriglyceridemia: A review of the evidence. Nurse Pract. 2018[citado 01/02/2020];43(10):22-29.Disponible en: https://journals.lww.com/tnpj/fulltext/2018/10000/Hypertriglyceridemia__A_review_of_the_evidence.6.aspx

  10. Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins–an integrated approach to mechanisms and disorders. N Engl J Med. 1967[citado 01/02/ 2020];276(5):273–281. Disponible en: https://www.nejm.org/doi/full/10.1056/NEJM196702022760507

  11. Masson W, Rossi E, Siniawski D, Damonte J, Halsband A, Barolo R, et al. Hipertrigliceridemia grave. Características clínicas y manejo terapéutico. Clín Investig Arterioscler. 2018[citado 01/02/2020];30(5):217-223. Disponible en: https://www.elsevier.es/es-revista-clinica-e-investigacion-arteriosclerosis-15-avance-resumen-hipertrigliceridemia-grave-caracteristicas-clinicas-manejo-S0214916818300494

  12. O’Dea LS, MacDougall J, Alexander VJ, Digenio A, Hubbard B, Arca M, et al. Differentiating Familial Chylomicronemia Syndrome From Multifactorial Severe Hypertriglyceridemia by Clinical Profiles. J Endocr Soc. 2019[citado 01/02/2020];3(12):2397–2410.Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6864364/pdf/js.2019-00214.pdf

  13. Toth PP, Philip S, Hull M, Granowitz C. Elevated Triglycerides (≥150 mg/dL) and High Triglycerides (200-499 mg/dL) Are Significant Predictors of New Heart Failure Diagnosis: A Real-World Analysis of High-Risk Statin-Treated Patients. Vasc Health Risk Manag. 2019[citado 01/02/ 2020];15:533-538. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6900310/pdf/vhrm-15-533.pdf

  14. Decharatchakul N, Settasatian C, Settasatian N, Komanasin N, Kukongviriyapan U, Intharaphet P, et al. Association of genetic polymorphisms in SOD2, SOD3, GPX3, and GSTT1 with hypertriglyceridemia and low HDL-C level in subjects with high risk of coronary artery disease. PeerJ. 2019[citado 01/02/ 2020]; 7: e7407. Disponible en: http://doi.org/10.7717/peerj.7407

  15. García Díaz JD, Mesa Latorre JM, Valbuena Parra AR, Corps Fernández D. Protocolo diagnóstico de las dislipidemias. Medicine. 2016[citado 01/02/2020];12(19):1107-1110. Disponible en: https://doi.org/10.1016/j.med.2016.09.022

  16. Miller M, Stone NJ, Ballantyne C, Ginsberg HN, Jacobson MS, Lennie TA, et al. Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2011[citado 01/02/2020];123:2292-2333. Disponible en: https://www.ahajournals.org/doi/pdf/10.1161/CIR.0b013e3182160726

  17. Jellinger PS, Handelsman Y, Rosenblit PD, Bloomgarden ZT, Fonseca VA, Garber AJ, et al. American Association of Clinical Endocrinologists and American College of Endocrinology guidelines for management of dyslipidemia and prevention of cardiovascular disease. Endocr Pract. 2017[citado 01/02/2020]; 23(Suppl 2):1-87. Disponible en: https://journals.aace.com/doi/pdf/10.4158/EP171764.APPGL

  18. Jacobson TA, Ito MK, Maki KC, Orringer CE, Bays HE, Jones PH, et al. National lipid association recommendations for patient-centered management of dyslipidemia: part 1—full report. J Clin Lipidol. 2015[citado 01/02/2020]; 9(2):129-169. Disponible en: https://doi.org/10.1016/j.jacl.2015.02.003

  19. Berglund L, Brunzell JD, Goldberg AC, Goldberg IJ, Sacks F, Muradet MH, et al. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012[citado 01/02/2020]; 97(9):2969-2989. Disponible en: https://doi.org/10.1210/jc.2011-3213

  20. Goldberg AC. Dislipidemia. En: Manual MSD. Versión para profesionales. USA: Merck; 2018. [citado 01/02/ 2020]; Disponible en: https://www.msdmanuals.com/es/professional/trastornos-endocrinol%C3%B3gicos-y-metab%C3%B3licos/trastornos-de-los-l%C3%ADpidos/dislipidemia?query=hipertrigliceridemia.

  21. Fernández A, Mazuecos L, Pintado C, Rubio B, López V, de Solís AJ, et al. Effects of Moderate Chronic Food Restriction on the Development of Postprandial Dyslipidemia with Ageing. Nutrients. 2019[citado 01/02/2020]; 11(8): 1865. Disponible en: https://doi.org/10.3390/nu11081865

  22. Kim SA, Lee JK, Kang D, Shin S. Oily Fish Consumption and the Risk of Dyslipidemia in Korean Adults: A Prospective Cohort Study Based on the Health Examinees Gem (HEXA-G) Study. Nutrients. 2019[citado 01/02/2020]; 11: 2506. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6835780/pdf/nutrients-11-02506.pdf

  23. Miguel PE, Peña I, Niño S, Cruz W, Niño A, Ponce D. Ensayo clínico aleatorio: papel de la dieta y ejercicios físicos en mujeres con síndrome metabólico. Aten Primaria. 2012 [citado 01/02/ 2020]; 44(7): 387-393. Disponible en: http://www.sciencedirect.com/science/article/pii/S0212656711004252

  24. Ochoa Expósito K, Rivas Estévez M, Miguel Soca PE, Batista Hernández A, Leyva Sicilia Y. Ensayo no aleatorizado: impacto de cambios en la dieta y ejercicios físicos en pacientes adultos con síndrome metabólico. CCM. 2015 [citado 02/02/20202];19(3).Disponible en: http://revcocmed.sld.cu/index.php/cocmed/article/view/2156

  25. Sheikh O, Vande Hei AG, Battisha A, Hammad T, Pham S, Chilton R. Cardiovascular, electrophysiologic, and hematologic effects of omega-3 fatty acids beyond reducing hypertriglyceridemia: as it pertains to the recently published REDUCE-IT trial. Cardiovasc Diabetol. 2019[citado 01/02/2020]; 18: 84. Disponible en: https://doi.org/10.1186/s12933-019-0887-0

  26. Kosmas CE, Sourlas A, Mallarkey G, Silverio D, Ynoa DY, Montan PD, et al. Therapeutic management of hyperlipoproteinemia (a). Drugs Context. 2019[citado 01/02/2020]; 8: 212609.Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6752750/pdf/dic-8-212609.pdf

  27. Shukla AK, Mehani R. Safety and efficacy of alirocumab: A meta analysis of 12 randomized controlled trials. J Family Med Prim Care. 2019[citado 01/02/2020]; 8(7): 2249–2257. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6691459/?report=classic

  28. Chaudhary R, Garg J, Shah N, Sumner A. PCSK9 inhibitors: A new era of lipid lowering therapy. World J Cardiol. 2017[citado 01/02/2020];9(2): 76-91. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5329749

  29. Poon SWY, Leung KKY, Tung JYL. Management of severe hypertriglyceridemia due to lipoprotein lipase deficiency in children. Endocrinol Diabetes Metab Case Rep. 2019[citado 01/02/2020]; 2019: 19-0052.Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6685095/pdf/EDM19-0052.pdf

  30. van Zwol W, Rimbert A, Kuivenhoven JA. The Future of Lipid-Lowering Therapy. J Clin Med. 2019[citado 01/02/2020];8(1085). Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6678580/pdf/jcm-08-01085.pdf

  31. Kim EJ, Wierzbicki AS. Cardiovascular prevention: Frontiers in lipid guidelines. Clin Med (Lond).2020[citado 01/02/2020]; 20(1): 36–42. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6964168/pdf/clinmed-20-1-36.pdf

  32. Alonso R, Cuevas A, Mata P. Lomitapide: a review of its clinical use, efficacy, and tolerability. Core Evid. 2019[citado 01/02/2020]; 14: 19–30. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6615460/pdf/ce-14-19.pdf




2020     |     www.medigraphic.com